PBT up 20.3% on Medical and Community gains, pharmacy result fell 13%

NPAT lifted 17.5% to NZ$11.4m, with the 2.8pp gap to PBT growth driven by the effective tax rate stepping up to 30.3% from 26.8% — also above the historical baseline mean of 27.4%.

Beneath the headline, the segment mix shifted decisively. Pharmacy services revenue grew but its segment result fell to NZ$11.6m from NZ$13.3m, and its share of group revenue declined to 50.6% from 54.5%. Medical services result rose to NZ$9.3m from NZ$5.7m and Community Health to NZ$6.6m from NZ$2.5m, together accounting for essentially all of the group's earnings uplift.

Operating cash flow lifted 62.5% to NZ$28.9m, and gross borrowings fell modestly to NZ$24.8m against cash of NZ$43.6m.

The dominant segment (still 50.6% of revenue) delivered a lower result on higher revenue, which means margin compression inside the largest business line. Same-store retail revenue growth of 8% (per commentary) did not flow through to segment profit, raising a question about cost inflation, mix, or rollout-related expense in Pharmacy.

Medical and Community Health are carrying the result. Medical services result is up roughly 63% and Community Health up roughly 166% from low bases, lifting the group's PBT margin to 6.0% versus a historical mean of 4.4%. Investors relying on a pharmacy-led thesis need to recognise the earnings engine has rotated, and the durability of these segment uplifts has not been tested across multiple periods.

Tax rate stepped up materially. The effective tax rate moved to 30.3% from 26.8% in the prior comparable, and sits 2.9pp above the three-period historical mean of 27.4%. Because this gap explains the 2.8pp PBT-to-NPAT growth divergence, the cleaner operating read here is PBT (+20.3%), not NPAT (+17.5%).

The supplied seasonality context shows HY22 contributed 46.2% of FY22 revenue but only 39.3% of FY22 NPAT, so FY23 has historically been second-half weighted on the bottom line. Annualising HY23 revenue gives NZ$710.2m versus an implied second half of NZ$360.4m if the prior pattern repeats — a marginal step-up, but contingent on segment-mix stability.

The release does not support a confident shape call because the Medical and Community uplifts are growing off small prior-period bases. The key uncertainty is whether the pharmacy margin pressure persists into the second half and whether Medical and Community can hold their step-change in result.

Pre-lease FCF of NZ$25.8m converted at 227.5% of NPAT, against a historical mean of NZ$18.1m, and capex remained low at 0.8% of revenue. Net cash position improved to NZ$18.9m from NZ$5.9m. Inventory days tightened to 16.6 from a historical mean of 23.5, which contributed to the cash uplift but raises a sustainability question if it reflects stock pull-forward rather than structural working-capital efficiency.

Two qualifiers temper the durability read. First, the supplied baseline classifies the NZ$2.5m operating working-capital build as upper edge of range, meaning cash generation benefited from a relatively contained build versus the prior period rather than a true release. Second, debtor days at 17.2 sit above the three-period historical mean of 10.0 (though down from 19.4 in the prior comparable), suggesting receivables growth that bears watching even though cash was collected this period.

This briefing cannot assess management's forward outlook or any specific FY23 target because no guidance was disclosed in the supplied release.